Skip to main content

Table 2 Echocardiologic evaluation of cardiac function at 2 and 7 days after AAC

From: Trimetazidine attenuates pressure overload-induced early cardiac energy dysfunction via regulation of neuropeptide Y system in a rat model of abdominal aortic constriction

 

2 days after AAC

7 days after AAC

Sham

AAC

AAC + TMZ

P values

Sham

AAC

AAC + TMZ

P values

IVSd (mm)

0.95 ± 0.12

1.00 ± 0.05

1.01 ± 0.06

>0.05

1.10 ± 0.03

1.21 ± 0.07

1.24 ± 0.11

>0.05

LVPWd (mm)

1.30 ± 0.40

1.63 ± 0.07

1.64 ± 0.04

>0.05

1.45 ± 0.19

1.67 ± 0.12

1.65 ± 0.23

>0.05

LVEDD (mm)

4.30 ± 0.27

4.53 ± 0.39

4.52 ± 0.26

>0.05

4.50 ± 0.28

4.90 ± 0.09

5.03 ± 0.12

>0.05

LVESD (mm)

2.46 ± 0.11

2.52 ± 0.09

2.51 ± 0.07

>0.05

2.49 ± 0.07

2.62 ± 0.24

2.64 ± 0.18

>0.05

LVFS (%)

37.97 ± 9.05

44.66 ± 10.04

45.27 ± 8.13

>0.05

38.63 ± 8.15

44.56 ± 1.89

43.68 ± 2.78

>0.05

LVEF (%)

73.47 ± 10.51

85.40 ± 1.91

84.23 ± 2.32

>0.05

79.5 ± 3.41

86.09 ± 3.19

84.48 ± 2.67

>0.05

  1. Data are presented as mean ± SD, n = 6 per group
  2. AAC aortic artery constriction, IVSd interventricular septal thickness at end diastole, LVPWd left ventricular posterior wall thickness at end diastole, LVEDD left ventricular end-diastolic dimension, LVESD left ventricular end-systolic dimension, LVFS left ventricular factional shortening, LVEF left ventricular ejection fraction, TMZ trimetazidine
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us